Use of low molecular weight heparin CY 222 during cardiopulmonary bypass. Experimental study and clinical application

Abstract

Cardiopulmonary bypass (CPB) standard heparin and protamine therapy is a relatively satisfactory part of conventional CPB practice. However, some problems are known to result from both heparin and protamine sulphate administration. These include: allergic reaction and thrombocytopenia due to heparin, and anaphylactoid reactions, negative inotropic effects, pulmonary oedema and pulmonary hypertension due to protamine administration.

Low molecular weight heparin (LMWH) should theoretically be superior decreasing the adverse effects of standard heparin. In addition, it should not require the use of protamine for heparin neutralization.

These potential benefits of LMWH encourage the experimental evaluation of the use of LMWH during open-heart surgery before preliminary clinical applications.